Skip to main content
Top
Published in: Clinical Rheumatology 4/2020

Open Access 01-04-2020 | Scleroderma | Brief Report

Defining genetic risk factors for scleroderma-associated interstitial lung disease

IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease

Authors: Carmel J. W. Stock, Angelo De Lauretis, Dina Visca, Cecile Daccord, Maria Kokosi, Vasilis Kouranos, George Margaritopoulos, Peter M. George, Philip L. Molyneaux, Svetlana Nihtyanova, Felix Chua, Toby M. Maher, Voon Ong, David J. Abraham, Christopher P. Denton, Athol U. Wells, Louise V. Wain, Elisabetta A. Renzoni

Published in: Clinical Rheumatology | Issue 4/2020

Login to get access

Abstract

Although several genetic associations with scleroderma (SSc) are defined, very little is known on genetic susceptibility to SSc-associated interstitial lung disease (SSc-ILD). A number of common polymorphisms have been associated with SSc-ILD, but most have not been replicated in separate populations. Four SNPs in IRF5, and one in each of STAT4, CD226 and IRAK1, selected as having been previously the most consistently associated with SSc-ILD, were genotyped in 612 SSc patients, of European descent, of whom 394 had ILD. The control population (n = 503) comprised individuals of European descent from the 1000 Genomes Project. After Bonferroni correction, two of the IRF5 SNPs, rs2004640 (OR (95% CI)1.30 (1.10–1.54), pcorr = 0.015) and rs10488631 (OR 1.48 (1.14–1.92), pcorr = 0.022), and the STAT4 SNP rs7574865 (OR 1.43 (1.18–1.73), pcorr = 0.0015) were significantly associated with SSc compared with controls. However, none of the SNPs were significantly different between patients with SSc-ILD and controls. Two SNPs in IRF5, rs10488631 (OR 1.72 (1.24–2.39), pcorr = 0.0098), and rs2004640 (OR 1.39 (1.11–1.75), pcorr = 0.03), showed a significant difference in allele frequency between controls and patients without ILD, as did STAT4 rs7574865 (OR 1.86 (1.45–2.38), pcorr = 6.6 × 10−6). A significant difference between SSc with and without ILD was only observed for STAT4 rs7574865, being less frequent in patients with ILD (OR 0.66 (0.51–0.85), pcorr = 0.0084). In conclusion, IRF5 rs2004640 and rs10488631, and STAT4 rs7574865 were significantly associated with SSc as a whole. Only STAT4 rs7574865 showed a significant difference in allele frequency in SSc-ILD, with the T allele being protective against ILD.
Key points
We confirm the associations of the IRF5 SNPs rs2004640 and rs10488631, and the STAT4 SNP rs7574865, with SSc as a whole.
None of the tested SNPs were risk factors for SSc-ILD specifically.
The STAT4 rs7574865 T allele was protective against the development of lung fibrosis in SSc patients.
Further work is required to understand the genetic basis of lung fibrosis in association with scleroderma.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Steen VD and Medsger, TA. Changes in causes of death in systemic sclerosis, 1972-2002.Ann Rheum Dis2007;66:940–944CrossRef Steen VD and Medsger, TA. Changes in causes of death in systemic sclerosis, 1972-2002.Ann Rheum Dis2007;66:940–944CrossRef
3.
go back to reference Reveille JD, Fischbach M, McNearney T et al (2001) Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. SeminArthritis Rheum 30:332–346 Reveille JD, Fischbach M, McNearney T et al (2001) Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. SeminArthritis Rheum 30:332–346
4.
go back to reference Sharif R, Mayes MD, Tan FK et al (2012) IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann.Rheum.Dis 71:1197–1202CrossRef Sharif R, Mayes MD, Tan FK et al (2012) IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann.Rheum.Dis 71:1197–1202CrossRef
5.
go back to reference Ito I, Kawaguchi Y, Kawasaki A et al (2009) Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 60:1845–1850CrossRef Ito I, Kawaguchi Y, Kawasaki A et al (2009) Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 60:1845–1850CrossRef
6.
go back to reference Xu Y, Wang W, Tian Y, Liu J, Yang R (2016) Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis. Int.J.Dermatol. 55:408–416CrossRef Xu Y, Wang W, Tian Y, Liu J, Yang R (2016) Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis. Int.J.Dermatol. 55:408–416CrossRef
7.
go back to reference Yi L, Wang JC, Guo XJ et al (2013) STAT4 is a genetic risk factor for systemic sclerosis in a Chinese population. Int.J.Immunopathol.Pharmacol 26:473–478CrossRef Yi L, Wang JC, Guo XJ et al (2013) STAT4 is a genetic risk factor for systemic sclerosis in a Chinese population. Int.J.Immunopathol.Pharmacol 26:473–478CrossRef
8.
go back to reference Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ, Broen JC, van Riel P, van 't Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, González-Gay MA, González-Escribano MF, Spanish Scleroderma Group, Airo P, van Laar J, Herrick A, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels P, Westhovens R, Kreuter A, Kiener H, de Baere E, Witte T, Padykov L, Klareskog L, Beretta L, Scorza R, Lie BA, Hoffmann-Vold AM, Carreira P, Varga J, Hinchcliff M, Gregersen PK, Lee AT, Ying J, Han Y, Weng SF, Amos CI, Wigley FM, Hummers L, Nelson JL, Agarwal SK, Assassi S, Gourh P, Tan FK, Koeleman BP, Arnett FC, Martin J, Mayes MD (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat.Genet. 42:426–429CrossRef Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ, Broen JC, van Riel P, van 't Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, González-Gay MA, González-Escribano MF, Spanish Scleroderma Group, Airo P, van Laar J, Herrick A, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels P, Westhovens R, Kreuter A, Kiener H, de Baere E, Witte T, Padykov L, Klareskog L, Beretta L, Scorza R, Lie BA, Hoffmann-Vold AM, Carreira P, Varga J, Hinchcliff M, Gregersen PK, Lee AT, Ying J, Han Y, Weng SF, Amos CI, Wigley FM, Hummers L, Nelson JL, Agarwal SK, Assassi S, Gourh P, Tan FK, Koeleman BP, Arnett FC, Martin J, Mayes MD (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat.Genet. 42:426–429CrossRef
9.
go back to reference Stock CJW, Renzoni EA (2018) Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. Eur.J.Hum.Genet 26:765–777CrossRef Stock CJW, Renzoni EA (2018) Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. Eur.J.Hum.Genet 26:765–777CrossRef
10.
go back to reference Dieude P, Guedj M, Wipff J et al (2009) Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 60:225–233CrossRef Dieude P, Guedj M, Wipff J et al (2009) Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 60:225–233CrossRef
11.
go back to reference Dieude P, Dawidowicz K, Guedj M, Legrain Y, Wipff J, Hachulla E, Diot E, Sibilia J, Mouthon L, Cabane J, Amoura Z, Crakowski JL, Carpentier P, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y (2010) Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J.Rheumatol. 37:987–992CrossRef Dieude P, Dawidowicz K, Guedj M, Legrain Y, Wipff J, Hachulla E, Diot E, Sibilia J, Mouthon L, Cabane J, Amoura Z, Crakowski JL, Carpentier P, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y (2010) Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J.Rheumatol. 37:987–992CrossRef
12.
go back to reference Wang J, Yi L, Guo X, Liu M, Li H, Zou H, Gu Y, Tu W, Guo G, Yang L, Lai S, He D, Zhou X (2014) Association of the IRF5 SNP rs2004640 with systemic sclerosis in Han Chinese. Int.J.Immunopathol.Pharmacol. 27:635–638CrossRef Wang J, Yi L, Guo X, Liu M, Li H, Zou H, Gu Y, Tu W, Guo G, Yang L, Lai S, He D, Zhou X (2014) Association of the IRF5 SNP rs2004640 with systemic sclerosis in Han Chinese. Int.J.Immunopathol.Pharmacol. 27:635–638CrossRef
13.
go back to reference Dieude P, Guedj M, Wipff J et al (2009) STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 60:2472–2479CrossRef Dieude P, Guedj M, Wipff J et al (2009) STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 60:2472–2479CrossRef
14.
go back to reference Dieude P, Guedj, M., Truchetet, ME. et al.Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum2011;63:1097–1105CrossRef Dieude P, Guedj, M., Truchetet, ME. et al.Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum2011;63:1097–1105CrossRef
15.
go back to reference Dieude P, Bouaziz M, Guedj M et al (2011) Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum 63:3979–3987CrossRef Dieude P, Bouaziz M, Guedj M et al (2011) Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum 63:3979–3987CrossRef
16.
go back to reference Carmona FD, Cenit MC, Diaz-Gallo LM et al (2013) New insight on the Xq28 association with systemic sclerosis. Ann.Rheum.Dis Carmona FD, Cenit MC, Diaz-Gallo LM et al (2013) New insight on the Xq28 association with systemic sclerosis. Ann.Rheum.Dis
17.
go back to reference (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581–590 (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581–590
18.
go back to reference Auton A, Brooks LD, Durbin RM et al (2015) A global reference for human genetic variation. Nature 526:68–74CrossRef Auton A, Brooks LD, Durbin RM et al (2015) A global reference for human genetic variation. Nature 526:68–74CrossRef
19.
go back to reference Wells AU, Desai, SR, Rubens, M. B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.Am J Respir Crit Care Med2003;167:962–969CrossRef Wells AU, Desai, SR, Rubens, M. B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.Am J Respir Crit Care Med2003;167:962–969CrossRef
20.
go back to reference Carmona FD, Martin JE, Beretta L et al (2013) The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS.One 8:e54419CrossRef Carmona FD, Martin JE, Beretta L et al (2013) The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS.One 8:e54419CrossRef
21.
go back to reference Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, Suárez H, Ortego-Centeno N, Riemekasten G, Fonollosa V, Vonk MC, van den Hoogen F, Sanchez-Román J, Aguirre-Zamorano MA, García-Portales R, Pros A, Camps MT, Gonzalez-Gay MA, Coenen MJ, Airo P, Beretta L, Scorza R, van Laar J, Gonzalez-Escribano MF, Nelson JL, Radstake TR, Martin J (2009) The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum.Mol.Genet. 18:2071–2077CrossRef Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, Suárez H, Ortego-Centeno N, Riemekasten G, Fonollosa V, Vonk MC, van den Hoogen F, Sanchez-Román J, Aguirre-Zamorano MA, García-Portales R, Pros A, Camps MT, Gonzalez-Gay MA, Coenen MJ, Airo P, Beretta L, Scorza R, van Laar J, Gonzalez-Escribano MF, Nelson JL, Radstake TR, Martin J (2009) The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum.Mol.Genet. 18:2071–2077CrossRef
22.
go back to reference Bossini-Castillo L, Simeon CP, Beretta L et al (2012) A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res.Ther 14:R85CrossRef Bossini-Castillo L, Simeon CP, Beretta L et al (2012) A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res.Ther 14:R85CrossRef
23.
go back to reference Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N.Engl.J.Med 354:2655–2666CrossRef Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N.Engl.J.Med 354:2655–2666CrossRef
24.
go back to reference Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir.Med 4:708–719CrossRef Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir.Med 4:708–719CrossRef
25.
go back to reference Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N.Engl.J.Med 380:2518–2528CrossRef Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N.Engl.J.Med 380:2518–2528CrossRef
26.
go back to reference Wu M, Assassi S, Salazar GA et al (2016) Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res.Ther 18:20CrossRef Wu M, Assassi S, Salazar GA et al (2016) Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res.Ther 18:20CrossRef
27.
go back to reference Stock CJ, Sato H, Fonseca C et al (2013) Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68:436–441CrossRef Stock CJ, Sato H, Fonseca C et al (2013) Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68:436–441CrossRef
28.
go back to reference Juge PA, Lee JS, Ebstein E et al (2018) MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N.Engl.J.Med 379:2209–2219CrossRef Juge PA, Lee JS, Ebstein E et al (2018) MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N.Engl.J.Med 379:2209–2219CrossRef
Metadata
Title
Defining genetic risk factors for scleroderma-associated interstitial lung disease
IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease
Authors
Carmel J. W. Stock
Angelo De Lauretis
Dina Visca
Cecile Daccord
Maria Kokosi
Vasilis Kouranos
George Margaritopoulos
Peter M. George
Philip L. Molyneaux
Svetlana Nihtyanova
Felix Chua
Toby M. Maher
Voon Ong
David J. Abraham
Christopher P. Denton
Athol U. Wells
Louise V. Wain
Elisabetta A. Renzoni
Publication date
01-04-2020
Publisher
Springer London
Keyword
Scleroderma
Published in
Clinical Rheumatology / Issue 4/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04922-6

Other articles of this Issue 4/2020

Clinical Rheumatology 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine